Cerenis Therapeutics s’introduit sur Euronext Paris


Paris – 30 March 2015– EnterNext, the Euronext subsidiary dedicated to promoting and growing the market for SMEs[1],today celebrated the listing of Cerenis Therapeutics, an international biopharmaceutical company dedicated to discovering and developing innovative HDL (“good cholestrol”) therapies for the treatment of cardiovascular and metabolic disease. Cerenis Therapeutics is listed on the Euronext Paris regulated market in Compartment B.

Founded in Toulouse, Cerenis is a biopharmaceutical company focusing on HDL therapies, one of the most promising therapeutic options for eliminating excess cholesterol and reducing atherosclerotic plaque. Developing one of the most advanced HDL solutions on the market – CER-001 – Cerenis can draw on solid resources to accelerate its product progress in meeting the pressing medical needs of nearly 3 million patients, and is positioned to capture a sizeable share of the market.

Cerenis Therapeutics (ticker symbol: CEREN) was listed through the admission to trading of 17,788,878 ordinary shares making up its equity, including 4,207,316 new shares issued under a Global Offering[2]after full exercise of the extension clause and the over-allotment option.

The Global Placement and Public Offering proved very popular with domestic and international investors, both retail and institutional.

The admission and issue price of Cerenis Therapeutics was set at €12.70 per share, at the high end of the price range. Market capitalisation on the day of listing was €226 million, and the operation raised a total of €53.4 million.

Jean-Louis Dasseux, Founder and CEO of Cerenis Therapeuticssaid:“Our extremely successful listing highlights the enormous potential of HDL therapy, one of the most effective treatments for cardiovascular disease. Investors’ enthusiasm also reflects CER-001’s position as frontrunner, with its development lead underpinned by a satisfactory safety and effectiveness profile, along with a proven mass production process. This new step in our business strategy positions us to better achieve our innovative drive to combat this 21st century plague more effectively. We are aware of the stakes and grateful to our shareholders, past and new, for their trust. And we would like to extend sincere thanks – bothto them and to our employees, who have played an essential role throughout our growth.”

Eric Forest, Chairman and CEO of EnterNext, said“We congratulate Cerenis Therapeutics on the largest round of equity finance raised by a French biotech company on Euronext Paris since 2000. The success and size of yet another listing of a company from southwestern France testifies once again to the region’s potential. Funds raised will allow Cerenis Therapeutics to step up deployment of its innovation-driven growth strategy.”

[1]Small and medium-size companies
The Global Offering was made up of a Public Offering that included an Open Price Public Offering and a Global Placement with institutional investors in France and other countries

Press Release Footer

About Euronext 
Euronext is the leading pan-European market infrastructure, connecting European economies to global capital markets, to accelerate innovation and sustainable growth. It operates regulated exchanges in Belgium, France, Ireland, Italy, the Netherlands, Norway and Portugal. With more than 1,900 listed issuers and around €6.5 trillion in market capitalisation as of end June 2023, it has an unmatched blue-chip franchise and a strong diverse domestic and international client base. Euronext operates regulated and transparent equity and derivatives markets, one of Europe’s leading electronic fixed income trading markets and is the largest centre for debt and funds listings in the world. Its total product offering includes Equities, FX, Exchange Traded Funds, Warrants & Certificates, Bonds, Derivatives, Commodities and Indices. The Group provides a multi-asset clearing house through Euronext Clearing, and custody and settlement services through Euronext Securities central securities depositories in Denmark, Italy, Norway and Portugal. Euronext also leverages its expertise in running markets by providing technology and managed services to third parties. In addition to its main regulated market, it also operates a number of junior markets, simplifying access to listing for SMEs.  
For the latest news, follow us on Twitter (twitter.com/euronext) and LinkedIn (linkedin.com/euronext).

This press release is for information purposes only and is not a recommendation to engage in investment activities. This press release is provided “as is” without representation or warranty of any kind. While all reasonable care has been taken to ensure the accuracy of the content, Euronext does not guarantee its accuracy or completeness. Euronext will not be held liable for any loss or damages of any nature ensuing from using, trusting or acting on information provided. No information set out or referred to in this publication may be regarded as creating any right or obligation. The creation of rights and obligations in respect of financial products that are traded on the exchanges operated by Euronext’s subsidiaries shall depend solely on the applicable rules of the market operator. All proprietary rights and interest in or connected with this publication shall vest in Euronext.

This press release speaks only as of this date. Euronext refers to Euronext N.V. and its affiliates. Information regarding trademarks and intellectual property rights of Euronext is located at www.euronext.com/terms-use.

© 2023, Euronext N.V. - All rights reserved.